Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35)...
Publication includes previously announced preclinical data of Auxora™ in acute kidney injury (AKI) models as well as a post-hoc...
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31)...
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $16 price tar...
